Ocular Therapeutix Sets Investor Day for June 2026 Amid Key Pipeline Developments
Event summary
- Ocular Therapeutix will host an Investor Day on June 17, 2026, in New York City with virtual access available.
- The event will feature senior leadership and retinal disease key opinion leaders.
- AXPAXLI (OTX-TKI), the company's investigational product for retinal disease, is in Phase 3 trials for wet AMD and diabetic retinal disease.
- DEXTENZA, an FDA-approved corticosteroid, and OTX-TIC, a travoprost hydrogel for glaucoma, are part of the company's pipeline.
The big picture
Ocular Therapeutix's Investor Day comes as the company navigates critical phases in its pipeline, particularly with AXPAXLI in Phase 3 trials. The event will provide insights into the company's strategy amid a competitive landscape in retinal disease treatments. The success of DEXTENZA and the potential of OTX-TIC will also be key focal points, reflecting the company's broader ambitions in ophthalmology.
What we're watching
- Clinical Progress
- The pace at which AXPAXLI advances through Phase 3 trials will determine its market potential in wet AMD and diabetic retinal disease.
- Pipeline Strategy
- Whether Ocular Therapeutix can leverage its ELUTYX technology to drive multiple product successes beyond DEXTENZA.
- Regulatory Pathway
- The timeline for OTX-TIC's next steps and its potential regulatory approval for glaucoma treatment.
Related topics